GLP-1 Drugs May Reach Only Half of Eligible Patients
Eli Lilly's CEO says structural barriers will cap GLP-1 weight-loss drug adoption at 40-50% of eligible patients, mirroring statin penetration rates.
Glp-1 Drugs
2 articles tagged "Glp-1 Drugs"
Novo Nordisk Faces Investor Pressure at 2026 Annual Meeting
Novo Nordisk faces shareholder scrutiny as its stock drops 45% since CEO ouster, while rival Eli Lilly surges to a $1 trillion market cap.